News Related to VEGFB

Related coverage linked through entity extraction aliases.

Samsung Bioepis settles Eylea biosimilar patent dispute, secures U.S. launch in 2027

Mar 02, 2026

Samsung Bioepis reached settlement agreements with Regeneron and Bayer for its aflibercept biosimilar OPUVIZ, enabling U.S. launch in January 2027 and staged international rollout beginning early 2026.

AAV Gene Therapy Advances for Neovascular AMD and Inherited Retinal Diseases

Feb 13, 2026

AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.